Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/171593
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ciruela Alférez, Francisco | - |
dc.contributor.author | Jacobson, Kenneth A. | - |
dc.date.accessioned | 2020-10-28T09:15:30Z | - |
dc.date.available | 2020-10-28T09:15:30Z | - |
dc.date.issued | 2019-01-23 | - |
dc.identifier.uri | http://hdl.handle.net/2445/171593 | - |
dc.description.abstract | The purine nucleotides and nucleosides constitute important extracellular signaling molecules acting as neurotransmitters and neuromodulators. Indeed, extracellular adenosine 5′-triphosphate (ATP) and adenosine, tightly controlled by nucleotidases, ribokinases, deaminases, and transporters, signal through a rich array of purinergic receptors. These receptors, which emerged early in evolution, are among the most abundant in living organisms controlling many physiological actions, thus becoming promising therapeutic targets in a wide range of pathological conditions. Thus, while P1 receptors are selective for adenosine, a breakdown product of ATP, P2 receptors are activated by purine nucleotides, as well as P2Y receptors being activated by pyrimidine nucleotides. Interestingly, purinergic receptors, both G protein-coupled (i.e., P1 and P2Y) and ligand-gated ion channel (i.e., P2X) receptors, are involved in many neuronal and non-neuronal mechanisms, including pain, immune responses, exocrine and endocrine secretion, platelet aggregation, endothelial-mediated vasodilatation and inflammation, among others. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fphar.2019.00021 | - |
dc.relation.ispartof | Frontiers In Pharmacology, 2019-01-23, Vol. 10, art. 21 | - |
dc.relation.uri | https://doi.org/10.3389/fphar.2019.00021 | - |
dc.rights | cc-by (c) Ciruela and Jacobson, 2019 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Proteïnes G | - |
dc.subject.classification | Neurociències | - |
dc.subject.other | G Proteins | - |
dc.subject.other | Neurosciences | - |
dc.title | Editorial: Purinergic Pharmacology | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-10-26T09:26:54Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 30728779 | - |
Appears in Collections: | Articles publicats en revistes (Institut de Neurociències (UBNeuro)) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) Articles publicats en revistes (Patologia i Terapèutica Experimental) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
CiruelaF.pdf | 191.93 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License